Clinical Trials Directory

Trials / Completed

CompletedNCT05995366

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration

Mass Balance Study of [14C] ABBV-903 in Healthy Male Subjects Following Single Oral Dose Administration

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
7 (actual)
Sponsor
AbbVie · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the mass balance and safety of \[14C\] ABBV-903 in healthy male volunteers following a single oral dose administration.

Conditions

Interventions

TypeNameDescription
DRUGABBV-903Solution; Oral

Timeline

Start date
2023-08-18
Primary completion
2023-10-13
Completion
2023-10-13
First posted
2023-08-16
Last updated
2023-10-26

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05995366. Inclusion in this directory is not an endorsement.